When administered exogenously, OXM can improve glucose tolerance and result in body weight loss, making GLP-1 and glucagon receptor dual agonists a promising treatment option for patients with T2D and/or obesity. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.